Adult Height Prediction in Congenital Adrenal Hyperplasia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

496 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-09-30

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Congenital Adrenal Hyperplasia (CAH) is a genetic rare disease, which alters the adrenal production of gluco and mineralo corticoïds. The treatment consists in supplementing children with hydrocortisone. Despite care for these children has improved substantially across decades, short adult height (AH) still remains an important consequence of the disease. About 20% of patients have an AH below 2 standard deviations compared to their expected AH.

In the OPALE-Model study, the investigators want to collect data from a cohort of 496 CAH French patients, born between 1970 and 1991 with a known genotype. Using their age, sex, growth, disease, bone maturation and pubertal data, the investigators will build a model which allows to predict their AH using data available at 8 years of age. The growth charts built from this cohort have shown that currently used formula to calculate the predicted AH (Bayley-Pineau's formula) is not applicable to children with CAH.

In this project, the investigators plan to compute an AH prediction model using data from children born between 1970 and 1993, and to validate the model using data from a different cohort (i.e. children born between 1994 and 1998). this choice was due to availability of data for computing the model first, and in a second stage, data from more recently born patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Growth Hormone (GH) in Congenital Adrenal Hyperplasia

NCT03162172

Adrenal Hyperplasia, Congenital

COMPLETED

COrticosteroid in Congenital Adrenal Hyperplasia

NCT02552251

Congenital Adrenal Hyperplasia

UNKNOWN PHASE2/PHASE3

Final Height in Patients With CAH

NCT04293133

Congenital Adrenal Hyperplasia

UNKNOWN

Linear Growth of Children With Congenital Adrenal Hyperplasia

NCT04087148

Congenital Adrenal Hyperplasia

UNKNOWN

Androgen Reduction in Congenital Adrenal Hyperplasia

NCT03548246

Congenital Adrenal Hyperplasia

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congenital Adrenal Hyperplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

cohort for model computing

patients with CAH, born between 1970 and 1993, with genetically proven CAH, available growth and bone maturation data.

Collection of growth and bone maturation data

Intervention Type OTHER

cohort for model validation

patients with CAH, born between 1994 and 1998, with genetically proven CAH, available growth and bone maturation data.

Collection of growth and bone maturation data

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Collection of growth and bone maturation data

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* children with CAH, genetically proven, classical form, virilizing form, with deficit of 21 hydroxylase, 11 beta hydroxylase, or 3 beta ol dehydrogenase, born between 1972-1993 (cohort 1) and 1994-1998 (cohort 2).
* medical charts should be available.

Exclusion Criteria

* Patients with chronic growth altering disease, Turner syndrome, or other genetic anomaly
* Patients having received any treatment with Growth Hormone (GH)

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No